Investing.com -- CervoMed Inc (NASDAQ:CRVO) stock jumped 9.3% in after-hours trading Thursday following the release of positive Phase 2b trial results for its dementia with Lewy bodies (DLB) treatment candidate.
The company’s experimental drug neflamapimod demonstrated significant improvements on primary and key secondary outcome measures in patients with DLB, particularly those without Alzheimer’s disease co-pathology. The trial results were presented at the 18th Clinical Trials on Alzheimer’s Disease Conference in San Diego.
Key findings showed neflamapimod reduced clinical worsening by 52% on the primary endpoint, Clinical Dementia Rating Sum of Boxes (CDR-SB), compared to control at 16 weeks. This effect was even more pronounced in patients with lower plasma ptau181 levels, showing an 82% reduction.
The drug’s efficacy appeared durable, with a 65% reduction in clinical worsening observed at 32 weeks across all participants. Patients who switched from placebo to the effective dose of neflamapimod showed a 1.12 point improvement in CDR-SB scores compared to their placebo period.
Importantly, the treatment also significantly reduced glial fibrillary acidic protein (GFAP), a biomarker of neuronal damage, suggesting the drug may address underlying disease mechanisms by targeting neuroinflammation and synaptic dysfunction.
"The magnitude of benefit and consistency of data across clinical measures in RewinD-LB provide great confidence that neflamapimod holds true potential to meaningfully slow clinical progression in DLB, a rapidly progressive disease with profound impact on patients and caregivers," said Dr. John-Paul Taylor, Professor at Newcastle University and principal investigator of the trial.
CervoMed is now preparing to initiate a Phase 3 registrational trial in the second half of 2026. The company noted that neflamapimod was well-tolerated with a low rate of treatment discontinuation over 48 weeks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
